T1	Participants 85 192	Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy
T2	Participants 1933 2054	patients with metastatic non-small cell lung cancer whose disease has progressed on or after platinum-based chemotherapy.
T3	Participants 352 477	patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy.
